Beta Bionics' Revenue Surge Masks a Year‑Long Slide

Rapid top‑line growth clashes with mounting losses and volatility

BBNX Beta Bionics, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

BBNX — Beta Bionics, Inc.

Healthcare · Medical - Equipment & Services $618.96M · Small Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

Limited Moat (Differentiation)

🔒 Product Differentiation

📈 Pricing Power

Weak

🏆 Market Position Niche Player

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +53.9% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

4.3x P/B

⚖️ Tier

Fair Value

📊 Beta 3.39 (High Volatility)

Beta Bionics, Inc. (BBNX) develops and commercializes implantable bioelectronic devices that restore endocrine function for patients with diabetes and other metabolic disorders, positioning it at the intersection of medical devices and digital health services. The company’s asset‑heavy model reflects substantial R&D spend and manufacturing capacity, yet its revenue has surged 53.9% YoY to $100 million, underscoring strong early market traction. Despite rapid top‑line growth, operating margins are deeply negative at -71.5%, reflecting the high cost of product development and regulatory rollout. Beta Bionics occupies a niche, differentiated segment with limited pricing power, making its valuation a fair‑value play for investors seeking exposure to high‑growth, defensively positioned healthcare innovation.

High revenue growth (+53.9% YoY) is driven by expanding adoption of its flagship artificial pancreas system, indicating strong product-market fit despite the company’s early stage.
The -71.5% operating margin highlights substantial cash burn required to scale manufacturing and secure regulatory approvals, necessitating careful monitoring of liquidity and financing needs.
Limited moat stems from product differentiation rather than network effects or patents, so competitive pressure could intensify if larger device makers enter the bioelectronic space.
Beta’s beta of 3.39 suggests amplified volatility relative to the market, which may appeal to risk‑tolerant investors looking for outsized upside in a defensively oriented healthcare niche.

Equity Performance & Market Positioning

Beta Bionics, Inc. (BBNX) — Stock Returns

Recent Performance

31.4%

1 Month

vs S&P +31.2

30.9%

3 Month

vs S&P +21.4

-54.3%

6 Month

vs S&P -62.1

-54.4%

YTD

vs S&P -62.3

-28.6%

1 Year

vs S&P -52.2

The 1‑month gain of +31.4% closely mirrors the S&P 500's +31.2% rally, indicating that BBNX moved in lockstep with broad market momentum rather than delivering stock‑specific alpha.
Over the past three months BBNX outperformed the index by roughly 9.5 percentage points (+30.9% vs +21.4%), suggesting a short‑term tailwind—likely from recent clinical trial updates—that resonated more strongly with investors than general market drivers.
The six‑month and YTD declines of -54.3% and -54.4% respectively are only marginally better than the S&P’s -62.1% and -62.3%, implying that BBNX's downside risk has been slightly mitigated but still tracks overall market weakness, reflecting sector‑wide pressure on biotech valuations.
The 1‑year performance of -28.6% versus the index's -52.2% shows that BBNX has held value better than the broader market, hinting at a relative resilience perhaps driven by its niche artificial pancreas pipeline.

Long-Term Performance (Annualized)

-32.6%

Full History

vs S&P -40.8

Across its full trading history BBNX has delivered an annualized return of -32.6%, underperforming the S&P's -40.8% by roughly 8 percentage points, indicating a modest long‑run defensive tilt relative to the broader market.
The negative trajectory reflects the high‑risk nature of early‑stage medical device firms, where regulatory milestones and reimbursement pathways heavily dictate stock performance.
Despite chronic underperformance, BBNX's less severe decline suggests that its core technology retains investor interest, providing a cushion against the full brunt of sector downturns.
The long‑term gap of 8% versus the index translates to roughly $0.80 of additional loss per $10 invested compared with a passive S&P exposure, a material difference for risk‑averse portfolios.

Highlight

BBNX's three‑month outperformance (+30.9% vs +21.4% for the S&P) is the most striking recent signal, as it demonstrates that company‑specific catalysts can generate meaningful excess returns even in a volatile biotech environment, offering a potential entry point for momentum‑focused investors.

Watch Out

Investors should be cautious that BBNX's historical -32.6% return still represents a substantial erosion of capital; any further regulatory setbacks or delays in commercial launch could deepen losses, potentially pushing cumulative underperformance beyond the current 8% margin relative to the S&P and eroding the modest defensive edge it currently enjoys.

Equity Performance & Market Positioning

Beta Bionics, Inc. (BBNX) — Risk & Smart Money

Risk Profile

73.9%

Volatility (20D)

3.39

Beta

-0.45

Sharpe Ratio

-72.3%

Max Drawdown (1Y)

89

RSI (14)

21%

52-Week Range

The 73.9% 52‑week volatility combined with a beta of 3.4 indicates that BBNX moves more than three times the market, exposing investors to extreme price swings on both upside and downside.
A Sharpe ratio of -0.4 signals that recent returns have been negative relative to the risk taken, suggesting the stock has underperformed on a risk‑adjusted basis.
The maximum drawdown of -72.3% shows that BBNX has lost nearly three‑quarters of its value from peak to trough, highlighting the potential for deep capital erosion during adverse phases.
An RSI of 89.3 places the stock in extreme overbought territory, implying short‑term price momentum may be exhausted and a corrective pullback is statistically more likely.

Smart Money Positioning

121.7%

Institutional Ownership

+13.5% QoQ

0.44

Insider Buy/Sell

Institutional ownership at 121.70% indicates that institutions collectively hold more shares than are available in the public float, suggesting aggressive long positioning and confidence in BBNX's long‑term pipeline.
The recent institutional change of +13.49% shows a net inflow of capital over the last reporting period, reinforcing the view that smart money is adding to exposure despite short‑term market turbulence.
Insider buying versus selling stands at 0.44 (net buy), meaning insiders are modestly accumulating shares, which often aligns management’s belief in near‑term catalysts such as regulatory approvals or product launches.
The combination of high institutional ownership and insider net buying creates a convergent signal that sophisticated investors expect value creation from upcoming clinical milestones.

Watch Out

However, the overbought RSI of 89.3 coupled with a -72.3% max drawdown suggests that smart money may be nearing a saturation point; if forthcoming data disappoints, the same aggressive positioning could accelerate sell‑offs, potentially amplifying losses beyond historical drawdowns.

Revenue, Earnings & Margin History

Beta Bionics, Inc. (BBNX) — Revenue & Growth

Revenue & Growth

Revenue surged to $100M, reflecting a 53.9% year‑over‑year increase that outpaces the median biotech growth rate of ~30%, indicating strong market adoption of Beta Bionics' core platform.
The three‑year CAGR of 724.3% demonstrates that revenue is scaling from a very low base, but such exponential growth may be difficult to sustain as the company moves into later stages of commercialization.
EPS remains negative at -$1.81, underscoring that earnings have not yet caught up with top‑line expansion and that the firm is still heavily reliant on financing rather than operating profitability.
R&D intensity of 34.7% of revenue signals a continued focus on pipeline development, which supports future growth but also contributes to the current earnings deficit.

Highlight

The 53.9% YoY revenue jump is the most compelling signal, as it shows Beta Bionics can translate its R&D spend into tangible sales momentum, bolstering the thesis that the company is transitioning from a pure development stage to early commercial traction.

Margin Evolution

Gross margin of 55.4% indicates a relatively high value capture on each unit sold, suggesting strong pricing power or low variable cost structure for its core products.
Operating margin of -71.5% and net margin of -73.0% reveal that operating expenses, chiefly R&D (34.7% of revenue) and stock‑based compensation (16.3% of revenue), are overwhelming gross profit and eroding cash generation.
Free cash flow at -56.1% of revenue highlights a significant cash burn, meaning the company must rely on external capital to fund ongoing operations and growth initiatives.
The combined weight of R&D and SBC expenses—over 50% of revenue—creates a cost base that will need to be rationalized or offset by higher sales volumes before margins can normalize.

Watch Out

The -71.5% operating margin translates to an operating loss of roughly $71.5M on $100M of revenue, posing a liquidity risk if the company cannot secure additional financing or improve cost efficiency within the next 12‑18 months.

Revenue, Earnings & Margin History

Beta Bionics, Inc. (BBNX) — 4-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+724.3%

💰 EPS

Revenue surged to $100M, reflecting a 53.9% year‑over‑year increase that outpaces the median biotech growth rate of ~30%, indicating strong market adoption of Beta Bionics' core platform.
The three‑year CAGR of 724.3% demonstrates that revenue is scaling from a very low base, but such exponential growth may be difficult to sustain as the company moves into later stages of commercialization.
EPS remains negative at -$1.81, underscoring that earnings have not yet caught up with top‑line expansion and that the firm is still heavily reliant on financing rather than operating profitability.
R&D intensity of 34.7% of revenue signals a continued focus on pipeline development, which supports future growth but also contributes to the current earnings deficit.

Profitability & Return on Capital

Beta Bionics, Inc. (BBNX) — DuPont & Efficiency

DuPont Decomposition (2025)

-25.5%

ROE

=

-73.0%

Net Margin

×

0.30x

Asset Turnover

×

1.1x

Eq. Multiplier

The dramatic swing in ROE from -498.1% to -25.5% is driven primarily by a collapse in net profit margin, which improved from an absurd -36,173.7% to -73.0%, indicating that earnings are still deeply negative relative to revenue.
Asset turnover (AT) rose tenfold from 0.01 to 0.30, showing the company is generating three cents of sales for every dollar of assets, a modest efficiency gain but insufficient to offset margin weakness.
The equity multiplier (EM) fell from 2.73 to 1.14, reflecting a reduction in financial leverage as the firm likely issued more equity or retired debt, which dampens ROE volatility but also limits upside potential.
Even after these improvements, the net loss per share remains large enough that ROE stays negative, signaling that the business model has not yet achieved profitability and investors should expect continued earnings erosion.

Highlight

The most notable profitability signal is the 13.8‑point rise in net profit margin to -73%, which, while still negative, represents a >99% reduction in loss intensity and suggests the firm may be moving toward breakeven if cost discipline continues.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	-25.5	-73.0	0.30	1.14	-28.4	-24.1	-22.3
2024	-72.0	-84.1	0.44	1.97	-36.7	-35.2	-36.6
2023	-75.2	-367.6	0.11	1.88	-36.1	-36.1	-40.1
2022	-498.1	-36173.7	0.01	2.73	-248.8	-247.0	-182.3

ROIC sits at -28.4%, indicating that invested capital is generating returns far below the cost of capital, a clear drag on shareholder value.
The cash conversion cycle (CCC) of 209 days signals prolonged working‑capital consumption, with inventory and receivables tied up for roughly seven months before cash is recovered.
Despite modest asset turnover improvement, the low AT of 0.30 means each dollar of assets produces only $0.30 of revenue, highlighting underutilized capital assets.
The decline in EM to 1.14 reduces leverage risk but also limits the firm’s ability to amplify returns on equity through debt financing.

Watch Out

A key efficiency red flag is the 209‑day CCC, which translates into an estimated $45 million of cash tied up in operating assets (assuming average daily sales of $215k); this liquidity strain could force additional financing or curtail growth initiatives.

Profitability & Return on Capital

Beta Bionics, Inc. (BBNX) — ROIC & Cash Conversion

Return on Invested Capital

Current-28.4%

Mean-87.5%

Min-248.8%

Max-28.4%

Range220.4pp

Cash Conversion Cycle

Current209d

Mean137d

Min0d

Max209d

ROIC sits at -28.4%, indicating that invested capital is generating returns far below the cost of capital, a clear drag on shareholder value.
The cash conversion cycle (CCC) of 209 days signals prolonged working‑capital consumption, with inventory and receivables tied up for roughly seven months before cash is recovered.
Despite modest asset turnover improvement, the low AT of 0.30 means each dollar of assets produces only $0.30 of revenue, highlighting underutilized capital assets.
The decline in EM to 1.14 reduces leverage risk but also limits the firm’s ability to amplify returns on equity through debt financing.

Profitability & Return on Capital

Beta Bionics, Inc. (BBNX) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

177d

Inventory Days

+

72d

Receivables Days

+

55d

Fixed Asset Days

≈

1197d

Total Asset Days

(0.30x turn)

Cash Conversion Cycle (2025)

177d

Inventory Days

+

72d

Receivables Days

−

41d

Payables Days

=

209d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	1197	177	72	55	41	209
2024	839	166	67	64	36	198
2023	3348	80	135	189	75	140
2022	72443	0	0	13985	0	0

The dramatic swing in ROE from -498.1% to -25.5% is driven primarily by a collapse in net profit margin, which improved from an absurd -36,173.7% to -73.0%, indicating that earnings are still deeply negative relative to revenue.
Asset turnover (AT) rose tenfold from 0.01 to 0.30, showing the company is generating three cents of sales for every dollar of assets, a modest efficiency gain but insufficient to offset margin weakness.
The equity multiplier (EM) fell from 2.73 to 1.14, reflecting a reduction in financial leverage as the firm likely issued more equity or retired debt, which dampens ROE volatility but also limits upside potential.
Even after these improvements, the net loss per share remains large enough that ROE stays negative, signaling that the business model has not yet achieved profitability and investors should expect continued earnings erosion.

Balance Sheet & Cash Flow Health

Beta Bionics, Inc. (BBNX) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$329M	$41M	$288M	$7M	$-24M	$32M	$268M	$31M
2024	$150M	$74M	$76M	$7M	$-23M	$30M	$133M	$21M
2023	$110M	$51M	$59M	$4M	$-22M	$27M	$104M	$11M
2022	$36M	$23M	$13M	$4M	$-24M	$28M	$28M	$9M

Liquidity & Solvency

5/9

Piotroski F-Score

Moderate

16.9

Altman Z-Score

Safe

The current ratio of 8.66 indicates that Beta Bionics holds $8.66 in current assets for every $1 of short‑term liabilities, far exceeding the 1.5 threshold and providing a wide cushion against liquidity shocks.
A debt‑to‑equity ratio of 0.03 reflects an extremely conservative capital structure, meaning only 3% of the firm’s financing comes from debt, which limits interest‑rate exposure and preserves equity value for shareholders.
Despite strong liquidity metrics, the negative free cash flow margin of -56.08% signals that operating cash is being heavily outpaced by capital expenditures, a pattern typical for high‑growth biotech firms investing in R&D and clinical trials.
Operating cash flow covering 70% of net income (OCF/NI = 0.70) shows that the majority of earnings are backed by cash generation, but the shortfall relative to the 1.0 benchmark suggests a reliance on accrual accounting or non‑cash items.

Balance Sheet & Cash Flow Health

Beta Bionics, Inc. (BBNX) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow
2025	$-51M	$-163M	$215M	$-5M	$-56M
2024	$-48M	$-3M	$56M	$-3M	$-52M
2023	$-32M	$-70M	$101M	$-0M	$-33M
2022	$-60M	$-1M	$57M	$-1M	$-61M

Cash Flow Trends

A Piotroski F‑Score of 5 out of 9 places Beta Bionics in the median range, indicating mixed signals on profitability, operating efficiency, and asset utilization that warrant close monitoring.
The Altman Z‑Score of 16.89 far exceeds the safety threshold of 2.99, signaling a very low probability of bankruptcy and underscoring the firm’s robust overall financial health despite its cash burn.
Cash conversion quality is reinforced by an OCF/NI ratio of 0.70, suggesting that earnings are largely cash‑based; however, the gap to the ideal >1.0 highlights the need for improved working‑capital management as the company scales.

Balance Sheet & Cash Flow Health

Beta Bionics, Inc. (BBNX) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F‑Score of 5 out of 9 places Beta Bionics in the median range, indicating mixed signals on profitability, operating efficiency, and asset utilization that warrant close monitoring.
The Altman Z‑Score of 16.89 far exceeds the safety threshold of 2.99, signaling a very low probability of bankruptcy and underscoring the firm’s robust overall financial health despite its cash burn.
Cash conversion quality is reinforced by an OCF/NI ratio of 0.70, suggesting that earnings are largely cash‑based; however, the gap to the ideal >1.0 highlights the need for improved working‑capital management as the company scales.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▼ -28.6%

vs S&P -52.2pp

Revenue 3Y CAGR

▲ +724.3%

Net Margin

-73.0%

▲ 3Y ago: -36173.7%

ROIC

-28.4%

▲ 3Y ago: -248.8%

FCF Margin

-56.1%

▲ 3Y ago: -34067.0%

Piotroski

5/9

Moderate

Beta Bionics (BBNX) has delivered a dismal total return of -28.6% over the past year, underperforming the S&P 500 by 52.2% while exhibiting extreme volatility (73.9%) and a high beta of 3.39, indicating pronounced sensitivity to market swings. Despite this weak price performance, the company’s top line surged 53.9% YoY to $100 million, propelled by an extraordinary 724.3% three‑year revenue CAGR, yet margins remain deeply negative with operating and net losses exceeding 70% of sales and EPS at -$1.81. The balance sheet is relatively sound—current ratio of 8.66, negligible debt (D/E 0.025), and a robust Altman Z‑score of 16.9—suggesting short‑term liquidity is not a concern, but cash conversion suffers with a 209‑day cash conversion cycle and free‑cash‑flow margin of -56%. The juxtaposition of rapid revenue growth against severe profitability deficits and high stock volatility creates a speculative profile: investors must weigh the upside of scaling revenues against the risk that losses and cash burn will erode value.

✅ Strengths

Revenue is expanding at a breakneck pace, with a 53.9% YoY increase to $100 M and a three‑year CAGR of 724.3%, indicating strong market demand for Beta Bionics' products and the potential to capture sizable share in its niche.
The company maintains an ultra‑conservative capital structure, evidenced by a debt‑to‑equity ratio of just 0.025 and a current ratio of 8.66, which provides ample liquidity cushion to fund ongoing R&D without refinancing risk.
An Altman Z‑score of 16.9 places BBNX well into the 'safe' zone, reinforcing that despite operating losses, the firm is unlikely to face imminent bankruptcy or solvency issues.

⚠️ Risks

Operating performance remains deeply negative, with an operating margin of -71.5% and net margin of -73.0%, meaning each dollar of revenue generates a substantial loss that must be financed through cash reserves or external capital.
Cash conversion is inefficient; the 209‑day cash conversion cycle combined with a free‑cash‑flow margin of -56.1% signals significant working‑capital pressure and ongoing cash burn that could exhaust liquidity if growth stalls.
Share price volatility is extreme (73.9% annualized) and beta is 3.39, so the stock is highly responsive to market sentiment; combined with a Sharpe ratio of -0.45, investors face a high risk‑adjusted return profile.

BBNX

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-08 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.